0001493152-24-012858.txt : 20240402 0001493152-24-012858.hdr.sgml : 20240402 20240402171936 ACCESSION NUMBER: 0001493152-24-012858 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240327 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240402 DATE AS OF CHANGE: 20240402 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INVO Bioscience, Inc. CENTRAL INDEX KEY: 0001417926 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 204036208 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-39701 FILM NUMBER: 24815628 BUSINESS ADDRESS: STREET 1: 5582 BROADCAST COURT CITY: SARASOTA STATE: FL ZIP: 34240 BUSINESS PHONE: (978) 878-9505 MAIL ADDRESS: STREET 1: 5582 BROADCAST COURT CITY: SARASOTA STATE: FL ZIP: 34240 FORMER COMPANY: FORMER CONFORMED NAME: EMY'S SALSA AJI DISTRIBUTION COMPANY, INC. DATE OF NAME CHANGE: 20071108 8-K/A 1 form8-ka.htm
true Amendment No. 1 0001417926 0001417926 2024-03-27 2024-03-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K/A

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): March 27, 2024

 

INVO BIOSCIENCE, INC.

(Exact name of registrant as specified in its charter)

 

Nevada   001-39701   20-4036208
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

5582 Broadcast Court

Sarasota, Florida 34240

(Address of principal executive offices)

(Zip Code)

 

Registrant’s telephone number, including area code: (978) 878-9505

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Common Stock, $0.0001 par value   INVO   The Nasdaq Stock Market LLC
(Title of Each Class)   (Trading Symbol)   (Name of Each Exchange on Which Registered)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (CFR §240.12b-2 of this chapter). Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

EXPLANATORY NOTE

 

INVO Bioscience, Inc. (the “Company”) is filing this Form 8-K/A to its Current Report on Form 8-K as originally filed with the Securities and Exchange Commission on April 1, 2024 (the “Original Filing”), solely to include Exhibit 5.1, which was inadvertently omitted from the Original Filing. No other changes have been made from the Original Filing.

 

Item 1.01 Entry into a Material Definitive Agreement.

 

On March 27, 2024, INVO Bioscience, Inc., a Nevada corporation (the “Company”) entered into a purchase agreement (the “Purchase Agreement”) with Triton Funds LP (“Triton”), pursuant to which the Company agreed to sell, and Triton agreed to purchase, upon the Company’s request in one or more transactions, up to 1,000,000 shares of the Company’s common stock, par value $0.0001 per share, providing aggregate gross proceeds to the Company of up to $850,000. Triton will purchase the shares of common stock under the Purchase Agreement at the price of $0.85 per share. The purchase agreement expires upon the earlier of the sale of all 1,000,000 shares of the Company’s common stock or December 31, 2024.

 

Among other limitations, unless otherwise agreed upon by Triton, each individual sale of shares of common stock will be limited to no more than the number of shares of common stock that would result in the direct or indirect beneficial ownership by Triton of more than 9.99% of the then-outstanding shares of common stock. In addition, the total cumulative number of shares of common stock that may be issued to Triton under the Purchase Agreement may not exceed the requirements of Nasdaq Listing Rule 5635(d), except that such limitation will not apply in the event the Company obtains stockholder approval of the shares of common stock to be issued under the Purchase Agreement, if necessary, in accordance with the requirements of Nasdaq Listing Rule 5635(d).

 

The Purchase Agreement provides that the Company will file a prospectus supplement (the “Prospectus Supplement”) to its Registration Statement on Form S-3, which was declared effective on April 16, 2021 (File No. 333-255096) (the “Base Registration Statement”), covering the offering and sale of the shares of common stock to Triton pursuant to the Purchase Agreement. Triton’s obligation to purchase shares of common stock under the Purchase Agreement is conditioned upon, among other things, the filing of the Prospectus Supplement and the Base Registration Statement remaining effective.

 

The Purchase Agreement contains customary representations, warranties, and covenants by each of the Company and Triton. Actual sales of shares of common stock to Triton will depend on a variety of factors to be determined by the Company from time to time, including, among others, market conditions, the trading price of the common stock and determinations by the Company as to the appropriate sources of funding for the Company and its operations. Triton has no right to require any sales of shares of common stock by the Company but is obligated to make purchases of shares of common stock from the Company from time to time, pursuant to directions from the Company, in accordance with the Purchase Agreement. During the term of the Purchase Agreement, Triton has covenanted not to cause or engage in any short selling of shares of common stock.

 

The foregoing description of the Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the Purchase Agreement, which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.

 

Item 3.02 Unregistered Sale of Equity Securities.

 

On March 27, 2024, the Company sold to Triton private placement warrants to purchase up to 1,000,000 shares of our common stock at an exercise price of $2.00 per share.

 

The private placement warrants and the shares of common stock issuable upon the exercise of such warrants have not been registered under the Securities Act are not being offered pursuant to this prospectus supplement and the accompanying prospectus and are being offered pursuant to an exemption provided in Section 4(a)(2) under the Securities Act and Rule 506(b) promulgated thereunder. Accordingly, the holder may only sell the private placement warrants and the shares of common stock issued upon exercise of the private placement warrants pursuant to an effective registration statement under the Securities Act covering the resale of those shares, an exemption under Rule 144 under the Securities Act or another applicable exemption under the Securities Act.

 

The following sets forth the material terms of the private placement warrants.

 

 

 

 

Exercisability. The private placement warrants will be immediately exercisable and will expire five years from the issuance date. The private placement warrants will be exercisable, at the option of each holder, in whole or in part by delivering to the Company a duly executed exercise notice and, at any time a registration statement registering the issuance of the shares of common stock underlying the private placement warrants under the Securities Act is effective and available for the issuance of such shares, or an exemption from registration under the Securities Act is available for the issuance of such shares, by payment in full in immediately available funds for the number of shares of common stock purchased upon such exercise. If a registration statement registering the issuance of the shares of common stock underlying the private placement warrants under the Securities Act is not effective or available, the holder may, in its sole discretion, elect to exercise the private placement warrants through a cashless exercise, in which case the holder would receive upon such exercise the net number of shares of common stock determined according to the formula set forth in the warrant.

 

Exercise Limitation. A holder will not have the right to exercise any portion of the private placement warrants if the holder (together with its affiliates) would beneficially own in excess of 9.99% of the number of shares of the Company’s common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the private placement warrants. However, the holder may increase or decrease such percentage, provided that any increase will not be effective until the 61st day after such election.

 

Trading Market Regulation. Until the Company has obtained stockholder approval of the purchase agreement and the private placement warrants, the Company may not issue any shares of common stock upon the exercise of the private placement warrants if the issuance of such shares, (taken together with the issuance of any shares held by or issuable to the holder under the Purchase Agreement or any other agreement with us) would exceed the aggregate number of shares which the Company may issue without breaching 523,344 shares (19.9% of the Company’s outstanding common stock) or any of the Company’s obligations under the rules or regulations of Nasdaq.

 

Exercise Price Adjustment. The exercise price of the private placement warrants is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Company’’s common stock and also upon any distributions of assets, including cash, stock or other property to our stockholders. If the Company receives stockholder approval for the issuance of the private placement warrants, the exercise price will be subject to adjustment if we issue additional shares of common stock at a price per share that is less than the exercise price then in effect.

 

Exchange Listing. There is no established trading market for the private placement warrants and the Company does not expect a market to develop. In addition, the Company does not intend to apply for the listing of the private placement warrants on any national securities exchange or other trading market.

 

Fundamental Transactions. If a fundamental transaction occurs, then the successor entity will succeed to, and be substituted for the Company, and may exercise every right and power that the Company may exercise and will assume all of the Company’s obligations under the private placement warrants with the same effect as if such successor entity had been named in the warrant itself. If holders of the Company’s common stock are given a choice as to the securities, cash, or property to be received in a fundamental transaction, then the holder shall be given the same choice as to the consideration it receives upon any exercise of the private placement warrants following such fundamental transaction.

 

Rights as a Stockholder. Except as otherwise provided in the private placement warrants or by virtue of such holder’s ownership of shares of the Company’s common stock, the holder of private placement warrants will not have the rights or privileges of a holder of the Company’s common stock, including any voting rights, until the holder exercises the warrant.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit   Description
     
4.1  

Common Stock Purchase Warrant dated March 27, 2024, filed as Exhibit 4.1 to our Current Report filed with the Securities and Exchange Commission on April 1, 2024 and incorporated herein by reference.

     
5.1  

Legal Opinion of Glaser Weil Fink Howard Jordan & Shapiro LLP

     
10.1   Purchase Agreement by and between INVO Bioscience, Inc. and Triton Funds LP dated as of March 27, 2024, filed as Exhibit 10.1 to our Current Report filed with the Securities and Exchange Commission on April 1, 2024 and incorporated herein by reference.
     
23.1  

Consent of Glaser Weil Fink Howard Jordan & Shapiro LLP (included in Exhibit 5.1)

     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: April 2, 2024

 

  INVO BIOSCIENCE, INC.
     
  By: /s/ Steven Shum
    Steven Shum
    Chief Executive Officer

 

 

 EX-5.1 2 ex5-1.htm

 

Exhibit 5.1

 

GW logo color 600dpi no tag  

10250 Constellation Blvd.

19th Floor

Los Angeles, CA 90067

310.553.3000 TEL

310.556.2920 FAX

 

March 29, 2024

 

INVO Bioscience, Inc.

5582 Broadcast Court

Sarasota, FL 24240

 

Re:

INVO Bioscience, Inc.

Registration Statement on Form S-3

 

To whom it may concern:

 

We are special counsel to INVO Bioscience, Inc., a Nevada corporation, (the “Company”) in connection with the preparation and filing with the Securities and Exchange Commission (the “Commission”) of a Prospectus Supplement (the “Prospectus Supplement”) on the date hereof pursuant to the Securities Act of 1933, as amended (the “Securities Act”), which is part of the Company’s Registration Statement on Form S-3 (Registration No. 333-255096) (the “Registration Statement”) and base prospectus (the “Base Prospectus”) that were filed with the Commission on April 7, 2021 and became effective on April 16, 2021, relating to the issuance and sale by the Company to Triton Funds LP (the “Investor”) of) up to 1,000,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) pursuant to that certain Purchase Agreement, dated March 27, 2024, by and between the Company and the Investor (the “Purchase Agreement”).

 

As such counsel, in rendering the opinion set forth below, we have made such investigations and examined and relied upon originals or copies, certified or otherwise, identified to our satisfaction of such records of corporate proceedings, certificates of public officials and officers of the Company, and other certificates and instruments relating to the authorization and issuance of such shares of Common Stock as we have deemed relevant and necessary for the opinion hereinafter expressed and other documents as we have considered to be necessary or relevant for the purposes of the opinion hereinafter expressed. In addition, we have reviewed and relied upon certain of the Company’s filings with the United States Securities & Exchange Commission (“SEC”), which are publicly available on the SEC’s website at sec.gov and the SEC’s EDGAR database located therein (the “EDGAR Database”).

 

 

 
 

 

INVO Bioscience, Inc.

March 29, 2024

Page 2

 

In rendering this opinion, we have relied, to the extent we deem such reliance appropriate, on certificates of officers of the Company as to factual matters regarding the Company and the transactions described in the Prospectus Supplement, Registration Statement, and Base Prospectus that were not readily ascertainable by us. In all such examinations and in giving our opinion, we have assumed that all documents identified in the EDGAR Database as filed by the Company were filed with the SEC on the dates set forth on the EDGAR Database. We have further assumed the conformity to authentic original documents of all documents identified in the EDGAR Database as filed by the Company, the conformity to authentic original signatures of all conformed signatures set forth in the documents identified in the EDGAR Database as filed by the Company with the SEC, and the genuineness of all such signatures. We have further assumed the genuineness of all signatures (including .PDF, DocuSign, or other generally accepted electronic signatures and signatures delivered by facsimile), the legal capacity and competency at all relevant times of all natural persons signing any documents, the authenticity of all documents submitted to us as originals, the conformity to authentic original documents of all documents submitted to us as certified, authenticated, conformed, notarized, photostatic, facsimile, or electronic copies and the authenticity of the originals of such certified, authenticated, conformed, notarized, photostatic, .PDF, or facsimile copies. We have further assumed that all facts set forth in the official public records, certificates, and documents supplied by public officials or otherwise conveyed to us by public officials are complete, true, and accurate. We have also assumed that all facts set forth in any certificates supplied by the Company (including, without limitation, the board resolutions pursuant to which the Shares are to be issued) or by the Investor are complete, true, and accurate.

 

It is understood that this opinion is to be used only in connection with the offer and sale of the Securities being registered while the Registration Statement is effective under the Securities Act.

 

Based upon the foregoing, we are of the opinion that the Shares, when issued and paid for in accordance with the terms of the Purchase Agreement, will be validly issued, fully paid, and non-assessable.

 

We are admitted to practice law in the State of California, and we render this opinion only with respect to, and express no opinion herein concerning the application or effect of the laws of any jurisdiction other than, the existing laws of the United States of America, the State of California and the existing Nevada Revised Statutes and reported judicial decisions relating thereto.

 

 
 

 

INVO Bioscience, Inc.

March 29, 2024

Page 3

 

We hereby consent to the use of this opinion as an exhibit to the Registration Statement and further consent to the use of our name wherever appearing in the Registration Statement, including the prospectuses constituting a part thereof and any amendment thereto. In giving the foregoing consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Securities and Exchange Commission promulgated thereunder.

 

This opinion speaks only as of the date above written. We assume no duty to update, revise, or supplement this opinion or to communicate with you with respect to any change in law that comes to our attention hereafter.

 

Very truly yours,

 

/s/ GLASER WEIL FINK HOWARD JORDAN & SHAPIRO LLP

 

GLASER WEIL FINK HOWARD JORDAN & SHAPIRO LLP

 

 

 

 GRAPHIC 3 ex5-1_001.jpg begin 644 ex5-1_001.jpg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end GRAPHIC 4 ex5-1_002.jpg begin 644 ex5-1_002.jpg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end EX-101.SCH 5 invo-20240327.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 6 invo-20240327_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 invo-20240327_pre.xml XBRL PRESENTATION FILE XML 9 R1.htm IDEA: XBRL DOCUMENT v3.24.1
Cover
Mar. 27, 2024
Cover [Abstract]  
Document Type 8-K/A
Amendment Flag true
Amendment Description Amendment No. 1
Document Period End Date Mar. 27, 2024
Entity File Number 001-39701
Entity Registrant Name INVO BIOSCIENCE, INC.
Entity Central Index Key 0001417926
Entity Tax Identification Number 20-4036208
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 5582 Broadcast Court
Entity Address, City or Town Sarasota
Entity Address, State or Province FL
Entity Address, Postal Zip Code 34240
City Area Code (978)
Local Phone Number 878-9505
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value
Trading Symbol INVO
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://invobioscience.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-ka.htm invo-20240327.xsd invo-20240327_lab.xml invo-20240327_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-ka.htm": { "nsprefix": "INVO", "nsuri": "http://invobioscience.com/20240327", "dts": { "inline": { "local": [ "form8-ka.htm" ] }, "schema": { "local": [ "invo-20240327.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "invo-20240327_lab.xml" ] }, "presentationLink": { "local": [ "invo-20240327_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://invobioscience.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-03-27", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-27", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-ka.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://invobioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 17 0001493152-24-012858-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-012858-xbrl.zip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end XML 19 form8-ka_htm.xml IDEA: XBRL DOCUMENT 0001417926 2024-03-27 2024-03-27 iso4217:USD shares iso4217:USD shares true Amendment No. 1 0001417926 8-K/A 2024-03-27 INVO BIOSCIENCE, INC. NV 001-39701 20-4036208 5582 Broadcast Court Sarasota FL 34240 (978) 878-9505 false false false false Common Stock, $0.0001 par value INVO NASDAQ false